Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.

作者
Hyo Sook Han,Ricardo Lima Barros Costa,Avan J. Armaghani,Susan J. Hoover,John V. Kiluk,Marie Catherine Lee,Hatem Hussein Soliman,Hung T. Khong,Loretta Loftus,Qianxing Mo,Jennifer A. Childress,Edith Abraham,Kaitlin Hendrix,Amy L. Aldrich,Marina Sehovic,Zena Jameel,Shannon Falcon,Robert Jared Weinfurtner,Aixa Elena Soyano Muller,Brian J. Czerniecki
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 596-596 被引量:1
标识
DOI:10.1200/jco.2023.41.16_suppl.596
摘要

596 Background: Early stage HER2 positive breast cancer (BC) patients (pts) are commonly treated with neoadjuvant HER2-targeted therapy. Optimizing neoadjuvant therapy by improving efficacy while reducing toxicity is a critical unmet need. IT DC 1 therapy combined with an IgG1 antibody mediating ADCC drives strong anti-HER-2 CD4 Th1 responses and complete tumor regression in preclinical models. We initiated a phase I/II neoadjuvant study to explore the efficacy and immune stimulation effects of an initial 6 weeks of immunotherapy phase (IP) using IT DC1 vaccine plus trastuzumab (H) and pertuzumab (P) (as source of IgG1) followed by 12 weeks of paclitaxel (T) and HP. Methods: Early stage HER2+ BC pts with tumor ≥ 1cm were eligible. Treatment included IT DC1 weekly x6 followed by paclitaxel 80 mg/m2 IV weekly x 12. Trastuzumab IV every (q) 3 weeks (8 mg/kg loading dose, then 6 mg/m2) and pertuzumab IV q 3 weeks (840 mg loading dose, then 420 mg) x 6 cycles starting from day 1. Two dose levels (DL) of IT DC1 (DL1 = 50 million and DL2 = 100 million cells) were evaluated including 6 pts in each DL. Once the optimal DL is determined based on toxicities, additional 22 patients will be enrolled in expansion phase 2 trial. The primary end point of the phase 1 is the safety, immune responses (measured by ELISPOT). MRI breast was performed at the baseline, post-immunotherapy and post-chemotherapy. Here we are reporting the safety and immune correlates in phase 1 study. Results: Twelve pts were enrolled between 10/2021 and 10/2022. Median age was 57 (range 34-74). Nine pts had hormone receptor positive disease with clinical stage I/II/III (5/5/2) and 4 pts had node positive disease. All pts completed IP and 10 patients completed THP chemotherapy as of 2/1/2023. Radiologic response per MRI breast on pre and post-IP showed 6 partial response, 3 complete response and 3 stable disease. Nine pts underwent surgery and 6 out of 9 pts had pCR (RCB 0). The most frequently observed toxicities were chills (50%), diarrhea (42%), nausea (42%), fatigue (42%), and headache (42%). ELISPOT demonstrated a significant decrease of HER2- specific T cell response following 6 weeks of DC1 IT injections in DL2 compared to DL1. Conclusions: The addition of IT DC1/HP to neoadjuvant chemotherapy was well tolerated with manageable toxicities. The 100 million DC1 led to a significant decrease in peripherally circulating anti-HER2 T cell response at week 6 following IP and improved radiologic tumor responses which correlates with a higher likelihood of pCR. Data from another IT DC1 trial suggests decreased circulating HER2 responsive T cells are due to increased trafficking of reactive T cells out of circulation into the tumor possibly leading to an enhanced anti-tumor effect. Updated results including correlative biomarkers will be presented at the meeting. Clinical trial information: NCT05325632 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
null的应助被waiting采纳,获得10
刚刚
小金人完成签到,获得积分10
刚刚
南瓜小笨111111完成签到 ,获得积分10
刚刚
小苦瓜完成签到,获得积分10
1秒前
1秒前
csz完成签到,获得积分10
2秒前
Candy完成签到 ,获得积分10
2秒前
JJD完成签到,获得积分10
2秒前
怕孤单的子默完成签到,获得积分10
3秒前
快乐小狗完成签到,获得积分10
3秒前
木心o完成签到,获得积分10
3秒前
雪霏完成签到 ,获得积分10
4秒前
4秒前
Mr.Ren完成签到,获得积分10
5秒前
hy完成签到,获得积分10
5秒前
Jonathan完成签到,获得积分10
6秒前
6秒前
Riley完成签到,获得积分10
7秒前
Crazy_Runner完成签到,获得积分10
8秒前
无花果的应助被快乐小狗采纳,获得10
9秒前
加贝完成签到,获得积分10
11秒前
复杂妙海完成签到,获得积分10
11秒前
踏实的水云完成签到,获得积分10
11秒前
科目三的应助被chemhub采纳,获得10
12秒前
GaoY完成签到,获得积分10
13秒前
Iris完成签到,获得积分10
13秒前
现实的傲薇完成签到,获得积分10
13秒前
13秒前
wq完成签到 ,获得积分10
14秒前
xhs12138完成签到,获得积分10
15秒前
15秒前
wuda完成签到,获得积分10
16秒前
xyj6486完成签到,获得积分10
16秒前
谨慎的佐罗完成签到,获得积分10
17秒前
17秒前
wanci的应助被加油的梨采纳,获得10
17秒前
小二郎的应助被乐乐采纳,获得10
17秒前
EE5577完成签到,获得积分10
18秒前
Egg完成签到 ,获得积分10
18秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428